Skip to main content
STTK
NASDAQ Life Sciences

Shattuck Q3 Loss Widens to $25.2M as R&D Spending Nearly Triples

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$5.5
Mkt Cap
$516.871M
52W Low
$1.72
52W High
$8.33
52W Position info
220% above low
Off High info
34% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

STTK has more than doubled off its 52-week low of $1.72.

Summary

Shattuck posted a Q3 net loss of $25.2 million, or $0.14 per share, versus a $10.1 million loss a year earlier, as R&D spending jumped to $21.6 million from $7.6 million. Cash and investments stood at $196.3 million at September 30, up from $86.1 million a year ago, and management says that funds operations into 2029. The quarter's real news is clinical: the company started the RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease, with 12-week induction data expected in the first half of 2028, and plans to start the RECEPTIVE-HS1 Phase 2 trial in hidradenitis suppurativa in the fourth quarter of 2026 after an October IND submission. It also presented preclinical SL-846 data at UEG Week 2026 and expects initial Phase 1 data for that bispecific in 2027. The wider loss is the cost of standing up two Phase 2 programs, and with the stock at $5.50 the runway removes near-term financing pressure; the next hard checkpoints are the HS trial start this quarter and management's fireside chats at the Evercore ISI conference November 30-December 1 and the Piper Sandler conference December 2-3.

At the time of this announcement, STTK was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $516.9M. The 52-week trading range was $1.72 to $8.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

STTK - Latest Insights

STTK
Nov 05, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $5.50 info
Change: $0 (0%) info
Market Cap: $516.871M info
STTK
Oct 01, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.79
Real-time Price: $5.50 info
Change: -$1.29 (-19%) info
Market Cap: $516.871M info
STTK
Aug 11, 2026, 6:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $5.50 info
Change: -$1.50 (-21%) info
Market Cap: $516.871M info
STTK
Aug 11, 2026, 6:57 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $5.50 info
Change: -$1.50 (-21%) info
Market Cap: $516.871M info
STTK
Aug 11, 2026, 6:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $5.50 info
Change: -$1.50 (-21%) info
Market Cap: $516.871M info